Tag: Lead Pharma
Company News: Lead Pharma Appoints Three Seasoned Industry Experts to its Supervisory Board
– Jan Egberts, M.D., Ir. Jan van der Hoeven and Daan van den Noort, M.D. join newly established Supervisory Board
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has appointed Dr. Jan Egberts, Ir. Jan van der Hoeven and Daan van den Noort to its newly established Supervisory Board.
Jan Egberts, M.D., has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer of Agendia Inc., a molecular diagnostics company. Prior to this, Dr. Egberts was Chief Executive Officer of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013. He also served as a Senior Healthcare Advisor for 3i Group plc and as President, Chairman and Chief Executive Officer of NovaDel Pharmaceuticals Inc. In addition, he held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care. Dr. Egberts, who graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, also serves on the Supervisory Board of several other private and public healthcare companies.
Ir. Jan van der Hoeven brings more than 30 years of experience in the biopharmaceutical industry. In 1983, he was co-founder of the CRO NOTOX, which he also headed until it was acquired by WIL Research Laboratories in 2006. In addition, since 1988 he has advised numerous life sciences companies, e.g. as a member of the Supervisory Board. He is also an ambassador of Wageningen University (Wageningen, The Netherlands). Before founding NOTOX, he worked as a scientist at Wageningen University for six years with emphasis on the relation of food and cancer. He (co-)authored over 30 scientific publications and has been awarded the EEMS Young Scientist Award in 1985. In 2003, he received the price for entrepreneurship from Wageningen University. Ir. van der Hoeven graduated from Wageningen University.
Daan van den Noort, M.D., brings over 25 years of experience as a manager and venture capitalist in the pharmaceutical and biotechnology industry in Europe. Among others, he served as General Manager for Genentech, Asta Medica, and Ferring in The Netherlands. From 2001 to 2011, he acted as the Chief investment Officer of the Biotech Turnaround Fund. He serves on several international boards of investment companies active in the biopharmaceutical industry. Mr. van den Noort holds an MD degree from the Free University of Amsterdam.
Company News: Lead Pharma to Partner with Sanofi on Development of Treatments for Autoimmune Diseases
– R&D collaboration and license agreement may yield potential first-in-class oral anti-ROR gamma (t) therapies
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has entered into a research collaboration and license agreement with Sanofi to discover, develop and commercialize small molecule therapies directed against the nuclear hormone receptor ROR gamma (t) to treat a broad range of autoimmune disorders, including common diseases such as rheumatoid arthritis and inflammatory bowel disease.
Researchers have identified 80 to 100 different autoimmune disorders and suspect at least an additional 40 diseases of being driven by immune function. These diseases are chronic and can be life-threatening.
Under the terms of the agreement, Lead Pharma will receive an upfront payment and is eligible to receive research, development, regulatory and commercial milestone payments. Further details of the financial terms have not been disclosed. Sanofi is responsible for clinical development and will have worldwide marketing and commercialization rights to any products that may be developed as a result of the collaboration. Lead Pharma is entitled to receive royalty payments on global sales from any such products.